Clinical Trials Logo

Dry Eye clinical trials

View clinical trials related to Dry Eye.

Filter by:

NCT ID: NCT05748951 Recruiting - Dry Eye Clinical Trials

Evaluating a Device for Blocking the Tear Duct

Start date: March 7, 2023
Phase: N/A
Study type: Interventional

Participants will receive a tear duct plug to see if their eye comfort improves.

NCT ID: NCT05737108 Recruiting - Dry Eye Clinical Trials

Bilberry-containing Capsules for Dry Eye Mitigation

Start date: August 24, 2022
Phase: N/A
Study type: Interventional

This study investigates whether the oral intake of a bilberry capsule product may relieve dry eye symptoms. Participants will be aged between 20 - 65 years of age, with confirmed diagnosis of dry eye status. The participants will be assessed for several parameters and asked to take 4 bilberry capsules per day for 30 days. The parameters will include ocular surface health, tear volume, tear quality, intraocular pressure, and tear compositions. After the 30 days are completed, the participants will be assessed again for the same parameters.

NCT ID: NCT05692739 Recruiting - Dry Eye Clinical Trials

Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye

Start date: October 5, 2022
Phase: Phase 4
Study type: Interventional

This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to the current gold standard treatment, cyclosporin and placebo (artificial tears).

NCT ID: NCT05605314 Recruiting - Dry Eye Clinical Trials

Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye

pSS
Start date: January 1, 2021
Phase:
Study type: Observational

Primary Sjögren's syndrome is a chronic autoimmune disease that primarily involves exocrine glands, most commonly manifested in dry eye, dry mouth, and in other systems of the body.

NCT ID: NCT05601011 Recruiting - Dry Eye Clinical Trials

Changes of Clinical Characteristics and Tear Film Biomarkers Following FS-LASIK

Start date: October 31, 2022
Phase:
Study type: Observational

to analyze the clinical and tear molecular profile up to 6 months after FS-LASIK surgery

NCT ID: NCT05600985 Recruiting - Dry Eye Clinical Trials

Clinical Characteristics of Patients Developing Chronic Dry Eye After Refractive Surgery

Start date: October 29, 2022
Phase:
Study type: Observational

In recent years, many scholars have studied the ocular surface damage of patients with dry eye disease(DED)after FS-LASIK, but there has been a lack of comprehensive observation and research on the relationship and difference between dry eye (DE)patients with and without LASIK. Therefore, the purpose of this study was to investigate the characteristics of ocular surface and cytokines after FS-LASIK, and further explain the pathogenesis of chronic dry eyes after FS-LASIK. In addition, we will also compare clinical characteristics and tear neuropeptide concentrations in patients with dry eye disease (DED) with and without chronic ocular pain following FS-LASIK, and to investigate correlations between ocular pain, clinical characteristics, and tear neuropeptide levels.

NCT ID: NCT05552820 Recruiting - Dry Eye Clinical Trials

Electroacupuncture for Mild-to-moderate Dry Eye

Start date: October 12, 2022
Phase: N/A
Study type: Interventional

To determine if electroacupuncture acts as an dry eye treatment rather than a placebo, and identify if benefits are linked to corneal subbasal nerve changes and neuroimmunomodulatory indicators.

NCT ID: NCT05383612 Recruiting - Dry Eye Clinical Trials

To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

MGD is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. It may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease. The meibomian glands, found in the upper and lower eyelids, excrete lipids onto the ocular surface that forms the outermost layer of the tear film, lubricating the ocular surface during blinking and protecting against tear evaporation.1 2 Through dysfunction of the meibomian glands, reduced lipid secretion may contribute to tear film instability and entry into the vicious circle of dry eye disease. The prevalence of MGD is higher in Asian populations, ranging from 46% to 70%. The management and treatment subcommittee of the International Workshop on MGD proposed a treatment algorithm in which treatment is added depending on the severity of MGD. The sequence of treatment addition is eyelid hygiene, eyelid warming and massage, artificial lubricants, topical azithromycin, topical emollient lubricant, oral tetracycline derivatives, lubricant ointment, and anti-inflammatory therapy. Topical diquafosol solution has been used to treat dry eye because it increases fluid secretion from conjunctival epithelial cells and mucin secretion from conjunctival goblet cells via the P2Y2 receptor. Because P2Y2 receptor expression is observed in sebaceous cells and ductal cells in the meibomian gland, diquafosol is expected to have some effects on meibomian glands. it has been reported that use 3% diquafosol ophthalmic solution in patients with obstructive MGD for more than 4 months. Ocular symptoms, lid margin abnormalities, the superficial punctate keratopathy score, and the meibum grade were decreased, while the tear breakup time, tear film meniscus area, and meibomian gland area were increased. These results suggest that topical diquafosol therapy is effective for patients with obstructive MGD. However, so far, no studies have reported the effect of DQS combined with eyelid hot compress and eyelid gland massage for MGD.

NCT ID: NCT05319041 Recruiting - Dry Eye Clinical Trials

Herbal Medication to Treat Dry Eye in Peri/ Post-menopausal Women

Start date: April 11, 2022
Phase: Early Phase 1
Study type: Interventional

Dry eye disease (DED) in less severe forms are very common, and should ideally be treated outside hospitals, eg., through primary care services and exploiting holistic therapies such as traditional medicine. This will keep the care affordable and accessible despite a large burden of care. Postmenopausal women, compared to others in the population, have a higher incidence of DED. Large-scale epidemiological studies done in the United States have shown that the rate of DED in women over 50 years old is nearly double that in men over 50, at 7% and 4%, respectively. Studies have demonstrated that there is a hormonal etiology behind this group's susceptibility to DED, although the precise hormonal imbalance and mechanistic pathway for DED are still unclear. A significant number of women seen at the dry eye clinic are post-menopausal, and very symptomatic, though many do not have the corneal epitheliopathy evidenced by dye staining. Such patients are not likely to benefit from conventional prescription drugs for dry eye, such as cyclosporine and corticosteroids. Hormonal replacement therapy for menopausal women has not been universally accepted, and there may be an increased risk of carcinomas, on the other hand, topical hormonal therapy for dry eye is not widely available, and still controversial, so there is a definite unmet need for new therapeutic modalities to treat dry eye in post-menopausal women. Traditional Chinese Medicine (TCM) is a form of complementary medicine that aims to treat yin or yang deficiency syndromes, using modalities like herbs, acupuncture or moxibustion. Menopause in women, particularly in Asia, has been linked to yin-deficiency, in one study, 73% of Chinese post-menopausal women suffered from kidney yin-deficiency. A review of randomized controlled trials of TCM treatment showed that certain modalities like soy and phytoestrogens have been useful in the treatment of syndromes in menopause, such as hot flushes.

NCT ID: NCT05306561 Recruiting - Dry Eye Clinical Trials

Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users

Start date: January 26, 2022
Phase: N/A
Study type: Interventional

To evaluate dry eye symptoms and contact lens wearing times after a single iLux treatment by evaluating change from baseline in OSDI scores, subjective CLDEQ8 and CL wearing time questionnaires, and meibomian gland secretion scores.